Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy

RTTNews | 652 days ago
Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy

(RTTNews) - Pharmaceutical companies Astellas Pharma Inc. (ALPMY.PK) and Poseida Therapeutics, Inc. (PSTX) announced Monday a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy.

Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8.3 million shares of common stock of Poseida or approximately 8.8% of the outstanding common stock of Poseida, at $3.00 per share in a private placement.

It will also make a one-time $25 million payment for a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs: P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.

In addition, Poseida has granted Astellas a board observer seat, which includes the ability to attend Poseida's scientific advisory board meetings, and certain notice rights related to any potential change of control of Poseida.

read more
Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
RTTNews | 424 days ago
Canadian Dollar Rises As Inflation Climbs

Canadian Dollar Rises As Inflation Climbs

The Canadian dollar advanced against its most major counterparts in the New York session on Tuesday, after a data showed that inflation accelerated in April.
RTTNews | 5h 26min ago
Swiss Market Ends Modestly Higher

Swiss Market Ends Modestly Higher

The Switzerland market suffered a mild setback in early trades on Tuesday, but recovered soon and then stayed firm right till the end of the session to finish with a modest gain. Investors tracked corporate news and the developments on the geopolitical front.
RTTNews | 6h 14min ago
European Stocks Recover After Weak Start, Close Broadly Higher

European Stocks Recover After Weak Start, Close Broadly Higher

European stocks closed broadly higher on Tuesday amid easing tariff worries, and expectations that Russia and Ukraine would soon begin ceasefire negotiations. The UK-EU trade agreement on Monday contributed as well to the positive mood in European markets.
RTTNews | 6h 35min ago
TSX Extends Gains To 10th Straight Session, Hits New Record High

TSX Extends Gains To 10th Straight Session, Hits New Record High

Canadian shares are up in positive territory Tuesday morning, extending gains to a tenth straight session, amid easing concerns about tariffs, and some brisk buying in gold stocks on safe-haven appeal following Moody's downgrading U.S. credit rating, citing debt concerns. Investors are also digesting a report showing a drop in Canada's annual inflation rate.
RTTNews | 8h 6min ago
Honda Cuts EV Sales, Investment Targets As It Shifts Focus

Honda Cuts EV Sales, Investment Targets As It Shifts Focus

Honda Motor Co., Ltd. announced Tuesday that it is realigning automobile business strategy, with a cut in planned electric vehicle or EV sales ratio, and investment for automobile electrification due to the recent market slowdown. Meanwhile, Honda expects a minimal increase in investment related to Hybrid Electric Vehicle or HEV business.
RTTNews | 9h 6min ago